Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 321

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 7
Chunk 321
---
 in November 2024. No shares of common stock were sold under the BofA ATM Program prior to its termination.

In December 2024, we entered into a Sales Agreement with Leerink Partners LLC (Leerink) pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $150.0 million from time to time through Leerink, acting as our sales agent (the Leerink ATM Program). As of December 31, 2024, no shares of common stock had been sold under the Leerink ATM Program. We intend to use proceeds obtained from the sale of shares under the Leerink ATM Program, if any, for general corporate purposes.

Private Placement

In July 2023, we sold 257,466 shares of our common stock in a private placement transaction for which we received aggregate net proceeds of $4.9 million, net of offering expenses.

Cash Flows

Our consolidated cash flows were as follows (in thousands):

    Years Ended December 31,

    2024

    2023

    2022

    Net cash used in operating activities
     
    $
    (173,125
    )
     
    $
    (218,407
    )
     
    $
    (207,488
    )

    Net cash provided by (used in) investing activities

    103,446

    190,943

    (11,929
    )

    Net cash provided by (used in) financing activities

    92,683

    (34,966
    )

    (28,840
    )

    Net increase (decrease) in cash and cash equivalents and restricted cash
     
    $
    23,004

    $
    (62,430
    )
     
    $
    (248,257
    )

Cash Flows from Operating Activities

Our net cash used in operating activities for the year ended December 31, 2024 decreased by $45.3 million from the year ended December 31, 2023, largely as a result of lower operating expenses and increased cost reimbursement received from AbbVie under our ABBV-RGX-314 collaboration in 2024. We expect to continue to incur regular net cash outflows from operations for the foreseeable future as we continue the development and advancement of our product candidates and other research programs.

For the year ended December 31, 2024, our net cash used in operating activities of